Clinical Trial Update: Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

View source ↗

Summary

Completed clinical trial evaluating biomarkers predicting response to anti-angiogenic therapy in recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Ho Sung Kim | Conditions: Adult Glioblastoma, Magnetic Resonance Imaging | Status: COMPLETED